Stay updated on DSP-5336 in Relapsed AML Clinical Trial
Sign up to get notified when there's something new on the DSP-5336 in Relapsed AML Clinical Trial page.

Latest updates to the DSP-5336 in Relapsed AML Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange Detected- Added Horizon-1 Phase 1/2 study of Enzomenib (DSP-5336) in acute leukemia with multiple arms, SOC combinations, and a detailed global site list. Replaced the former DSP-5336 relapsed/refractory AML/ALL study description with the Horizon-1 protocol and expanded indications and design.SummaryDifference8%

- Check16 days agoChange DetectedRevision indicator updated to v3.5.0. The previous revision v3.4.3 was removed.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3; no visible content changes.SummaryDifference0.0%

- Check51 days agoChange DetectedAdded Revision: v3.4.2; Deleted Revision: v3.4.1.SummaryDifference0.0%

- Check59 days agoChange DetectedMinor revision update from v3.4.0 to v3.4.1; no impact on content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check81 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4 in the page footer. No study details, eligibility, contacts, or locations were altered.SummaryDifference0.0%

Stay in the know with updates to DSP-5336 in Relapsed AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DSP-5336 in Relapsed AML Clinical Trial page.